Chengdu Easton Biopharmaceuticals Co Ltd (688513) — Cash Flow Quality Index
Chengdu Easton Biopharmaceuticals Co Ltd (688513) has a Cash Flow Quality Index of 0.73x as of September 2025. Operating cash flow of CN¥61.35 Million is below net income of CN¥83.59 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore Chengdu Easton Biopharmaceuticals Co Ltd (688513) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Chengdu Easton Biopharmaceuticals Co Ltd Cash Flow Quality Index (2013–2025)
Historical Cash Flow Quality Index for Chengdu Easton Biopharmaceuticals Co Ltd across 13 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see 688513 cash generation efficiency.
Annual Cash Flow Quality Index for Chengdu Easton Biopharmaceuticals Co Ltd (2013–2025)
Year-by-year earnings quality comparison for Chengdu Easton Biopharmaceuticals Co Ltd.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.94x | CN¥264.94 Million | CN¥283.25 Million | ▼ -15.3% |
| 2024 | 1.10x | CN¥263.24 Million | CN¥238.23 Million | ▼ -9.0% |
| 2023 | 1.21x | CN¥275.25 Million | CN¥226.57 Million | ▲ +97.1% |
| 2022 | 0.62x | CN¥151.94 Million | CN¥246.52 Million | ▼ -2.9% |
| 2021 | 0.64x | CN¥147.60 Million | CN¥232.43 Million | ▼ -27.7% |
| 2020 | 0.88x | CN¥156.52 Million | CN¥178.16 Million | ▼ -32.7% |
| 2019 | 1.31x | CN¥141.83 Million | CN¥108.61 Million | ▲ +5.7% |
| 2018 | 1.24x | CN¥166.79 Million | CN¥135.02 Million | ▼ -7.2% |
| 2017 | 1.33x | CN¥85.70 Million | CN¥64.37 Million | ▼ -28.0% |
| 2016 | 1.85x | CN¥106.06 Million | CN¥57.32 Million | ▲ +37.7% |
| 2015 | 1.34x | CN¥50.57 Million | CN¥37.62 Million | ▼ -15.9% |
| 2014 | 1.60x | CN¥46.71 Million | CN¥29.23 Million | ▼ -16.3% |
| 2013 | 1.91x | CN¥28.12 Million | CN¥14.73 Million | — |